Pancreatic adenocarcinoma is an aggressive and highly lethal malignancy. Currently, gemcitabine is commonly used in patients with pancreatic cancer. However, the life expectancy of pancreatic cancer patients remains poor. We explored the possibility of increased anti-tumor activity by combining human tumor necrosis factor-alpha (hTNF-a) with current front-line therapy. Human TNF-a displays potent anti-tumor activity, but its use is limited by the toxicity of systemic administration. We developed a gene delivery approach using intratumoral injections of an adenoviral vector expressing hTNF-a, AdEgr.TNF.11D (TNFerade), to increase local concentrations of hTNF-a within the tumor, thereby maximizing local anti-tumor activity and yet minimizing the systemic toxicities. An ongoing phase III clinical trial is testing the efficacy of AdEgr.TNF.11D-injected intratumorally and combining with chemotherapy in locally advanced pancreatic cancer. In this study, we show that treatment with AdEgr.TNF.11D and gemcitabine results in a high level of hTNF-a expression in human pancreatic cancer cell lines. The combined treatment was well tolerated, highly active and produced marked delays in the growth of human pancreatic xenograft tumors relative to either agent alone. Our results strongly suggest that combination of AdEgr.TNF.11D and gemcitabine may be a potentially useful therapeutic approach for the improved treatment of pancreatic cancer.
Introduction
Pancreatic adenocarcinoma is a disease characterized by late presentation, low rates of resectability for cure, early dissemination and a poor overall prognosis. The overall 5-year survival for patients with advanced pancreatic cancer is less than 2%. 1 Since 1997, the drug gemcitabine has been a standard of care for patients with advanced pancreatic cancer. In a small randomized phase III trial, 18% of gemcitabine-treated pancreatic cancer patients survived for 1 year when compared with the standard of care at that time (5-fluorouracil) of 2%. 2 There is an urgent and unmet need for new therapies for this highly challenging human malignancy.
Gemcitabine's anti-cancer activity is attributed to cellphase-specific killing of tumor cells in the S-phase as well as blocking cell-cycle progression through the G1/Sphase. More specifically, gemcitabine is metabolized intracellularly and results in two metabolites: diphosphate and triphosphate nucleosides. Both these metabolites interfere with DNA synthesis 3 and inhibit cell growth. In addition, gemcitabine induces apoptosis in human pancreatic cancer cells through the induction of intracellular reactive oxygen species. 4 Our experimental concept is that the addition of gemcitabine to AdEgr.TNF.11D (also known as TNFerade biologic) leverages the potent human tumor necrosis factor-alpha (hTNF-a) protein. The hTNF-a has showed necrosis activity in a wide variety of cancer cells, selective apoptotic activity on tumor vasculature, and may have distal effects that suppress metastases. 5, 6 Induction of apoptosis is the likely primary mechanism of direct cytotoxicity by hTNF-a and is probably mediated through the TNFRI receptor present on most cell types. 5 The hTNF-a also induces apoptosis in tumorassociated endothelial cells and sensitizes the tumor cells to radiation 7 and chemotherapeutic drug. 8 As hTNF-a and gemcitabine have different mechanisms to inhibit cancer growth, we hypothesize that the combination of hTNF-a and gemcitabine will improve the anti-tumor effect of either agent alone.
Preclinical studies have shown that adenovirus vector hTNF-a under control of a constitutive promoter, although successful in producing partial and complete tumor regression, results in significant systemic activity. 9 To circumvent systemic activity, we used adenovirus vector with chemo-or radiation-inducible promoterdriven hTNF-a, AdEgr.TNF.11D (TNFerade). Using TNFerade, an adenoviral protein expression system, hTNF-a can be delivered directly to the tumor. This results in local high concentrations of hTNF-a within the tumor and limits the amount of hTNF-a released into the general circulatory system. By using this approach, the cytotoxic activities of hTNF-a is primarily restricted to the tumor while sparing non-target tissues. 10, 11 Currently, a phase III trial is ongoing with AdEgr.TNF.11D and radiation for patients with unresectable pancreatic disease with no evidence of metastatic disease at diagnosis. Initial study results (n ¼ 51 total patents) indicate that AdEgr.TNF.11D in combination with combined chemoradiotherapy may prolong patient survival. 12 On the basis of these encouraging clinical findings and the anti-tumor activity of gemcitabine, we propose that addition of hTNF-a to gemcitabine may provide additional therapeutic benefit to patients with advanced pancreatic cancer. We show here that the combination of AdEgr.TNF.11D and gemcitabine produces stronger anti-tumor activity in human pancreatic tumor models than either agent alone.
Materials and methods

Animals
Six-week-old, immunodeficient athymic nude, balb/c, female mice weighing 19-22 g were purchased from Harlan, USA, and were maintained under conventional conditions. The GenVec animal facility operates in accordance with the 'National Institutes of Health Guide for the Care and Use of Laboratory Animals' and complies with the Public Health Service policy on Humane Care and Use of Laboratory Animals. All the cancer experimental procedures were in compliance with the National Institutes of Health guidelines and Public Health Service policy for the care and welfare of animals. The current study was approved by the Institutional Animal Care and Use Committee of GenVec, Inc.
Cells
Human pancreatic cancer cell lines, MiaPaca2, AsPC1 and Panc1, were purchased from American Type Culture Collection, Manassas, VA. The MiaPaca2 and Panc1 cells were maintained in Dulbecco's modified Eagle's medium, whereas the AsPC1 cell line was cultured in RPMI 1640 (Cambrex, Walkersville, MD). All media were supplemented with 10% (v/v) heat-inactivated fetal bovine serum (HyClone, Logan, UT), 2mM glutamine (Invitrogen Corporation, Carlsbad, California) and antibiotics (100 mg ml -1 of streptomycin and 100 U ml -1 of penicillin; Invitrogen Corporation, Carlsbad, California). All cell lines were maintained at 37 1C in a humidified incubator containing 5% CO 2 .
Adenovirus vectors
AdEgr.TNF.11D is an E1, E4 and partial E3 deleted replication-deficient adenovirus serotype 5 vector containing the hTNF-a cDNA under the control of the early growth response-1 (Egr-1) promoter, which is responsive to radiation and clinically used chemotherapeutics. 13, 14 Adenovirus vectors were constructed using GenVec's AdFAST technology as described earlier. 10, 11, 15 AdEgr.TNF.11D was propagated and expanded using 293-ORF6 cells. Adenovirus particles were purified using three successive rounds of cesium chloride gradient centrifugation. Purified adenovirus particle was then disrupted with sodium dodecyl sulfate and the particle number was determined by optical density measurement at 260 nm on a spectrophotometer (Beckman Coulter Inc, CA). Viral titers were expressed as particle units (pu). The adenoviruses, AdEgr.11D and Adf.11D, were used at pu of 1.5 Â 10 12 and 9.6 Â 10 11 pu ml -1 , respectively. The adenovirus vector was formulated in final formulation buffer (Invitrogen Corporation, Carlsbad, CA) for storage and assayed for potency, purity, sterility and absence of replication competent genome. We used final formulation buffer as a vehicle control and Adf. In vitro quantification of hTNF-a Human pancreatic cancer cells (MiaPaca2, Panc1 and AsPC1) were grown in 24 well plates (1 Â 10 5 cells per well) and transfected with AdEgr.TNF.11D at 100 pu per cell (100 MOI) in 400 ml medium for 3 h at 37 1C, 5% CO 2 . Three hours after AdEgr.TNF.11D transfection, the vector was removed and the cells were exposed to increasing concentration of gemcitabine (0, 0.001, 0.01, 0.1, 1, 10 and 100 mg ml -1 ). The control (Mock) wells received medium only without AdEgr.TNF.11D. After 24 h, the gemcitabine medium was removed and gemcitabine-free medium added. After 72 h incubation with gemcitabine-free medium, the cells were lysed using 1% lysis reagent (Promega, Madison, WI) with protease inhibitors (Roche, Nutley, NJ) for 30 min at room temperature followed by freeze thaw cycle. The lysate mixture was centrifuged at 5000 RPM for 5 min at 4 1C. The hTNF-a levels were determined in the supernatant using an hTNF-a ELISA kit (Pierce, Rockford, IL) with a level detection of o2 pg ml -1 according to the manufacturer's instructions.
In vivo tumor growth study Human pancreatic cancer cell lines, MiaPaca2 and AsPC1, were used in this study. Female athymic nude mice were inoculated subcutaneously into the dorsal side of the right hind limb with cancer cells (3 Â 10 6 ) in a 100-ml suspension of serum-free medium. Tumors were measured with vernier calipers twice or thrice weekly. The tumor volume was calculated using the formula, tumor volume (mm 3 ) ¼ (length Â width 2 )/2. Animals were randomly assigned to treatment and control groups when their tumors reached a volume of 75-125 mm 3 after 7 and 10 days post AsPC1 and MiaPaca2 tumor cell implantation, respectively. There were five groups: vehicle, control vector (Adf.11D), AdEgr.TNF.11D, gemcitabine and AdEgr.TNF.11D plus gemcitabine. Each treatment group had eight animals. The mice with tumors were injected with vector, AdEgr.TNF.11D or Adf.11D, at a dose level of 1 Â 10 10 pu per 30 ml in vehicle directly into the tumor three times a week for 2 weeks followed by once a week for an additional 2 weeks (Figure 2 ). The mice in the control vehicle group received 30 ml of vehicle alone. Gemcitabine was given to mice intravenously through jugular vein once a week for 4 weeks at a dose level of 120 mg kg -1 based on total body weight. The mice were weighed two or three times per week throughout the study as an indicator of toxicity by the treatment.
Statistics
Quantitative data are reported as the mean ± s.d. For the in vitro studies, statistical analyzes were performed with Origin 7.5 software (Origin Laboratories, Northampton, MA). A Shapiro-Wilk normality test was performed to determine whether the samples followed a normal distribution. For normally distributed data, the means of treatment groups were compared by one-way analysis of variance. Tukey multiple comparisons were used to specify which groups differ at the predetermined P-values of o0.05. If the data were not normally distributed, the Mann-Whitney Test was performed. In all cases, P-values of o0.05 were considered significant. For the in vivo studies, the statistical analyses were performed by Dr William R. Fairwather, statistical consultant (Flower Valley Consulting, Inc, Rockville, MD). For each animal, the pattern of tumor growth was plotted, and the intercept and slope for each animal's tumor volume growth was derived. Analysis of variance was performed on the Day 0 size of tumor and on the log rate of tumor volume growth. For the latter response variable, the three degrees of freedom for treatment were subdivided into individual orthogonal contrasts of the main effects of each treatment (AdEgr.TNF.11D or gemcitabine) and the interaction of these treatments. No adjustment was needed or made because of the orthogonality of these effects. For both response variables, the four treatment groups (does not include control vector) were compared in pairs using Tukey's test. A P-value of 0.05 was taken as significant differences among groups.
Results
Gemcitabine induced expression of hTNF-a in AdEgr.TNF.11D infected human pancreatic cancer cells Earlier studies have showed clinically approved chemotherapeutic drugs, cisplatin, 5-fluorouracil, paclitaxel, cyclophosphamide and gemcitabine were able to induce Egr-1 promoter contained within AdEgr.TNF.11D and drive hTNF-a expression in human prostate and rat colon Figure 1 Evaluation of hTNF-a induction by gemcitabine in AdEgr.TNF.11D-transduced human pancreatic cancer cell lines. MiaPaca2, Panc1 and AsPC1 cells were grown in 24-well plates and transduced with AdEgr.TNF.11D at 100 pu per cell (100 MOI). Then, the cells were treated with gemcitabine as described in Materials and methods. Each bar represents the mean±s.d. of three determinations. The hTNF-a concentrations in all the samples were within the limit of assays. No measurable hTNF-a was detected in MiaPaca2 treated with gemcitabine at a dose of 1 mg ml -1 in the absence of AdEgr.TNF.11D. Also, there was no detectable endogenous hTNF-a found in these cells (mock). The number above each bar represents the fold over AdEgr.TNF.11D without gemcitabine. The 'n' and ' Á ' designate those groups in which the hTNF-a increase was significant (analysis of variance, followed by Tukey, or Mann-Whitney, Po0.05) compared with AdEgr.TNF.11D alone and AdEgr.TNF.11D plus gemcitabine with different concentrations, respectively. In MiaPaca2, the gemcitabine at 1 mg ml -1 dose induced significant hTNF-a from AdEgr.TNF.11D-transduced cells compared to gemcitabine with 0, 0.001, 01, 10 or 100 mg ml -1 . In Panc1, the hTNF-a expression was significantly abundant (Po0.05) in cells treated with AdEgr.TNF.11D plus gemcitabine 1 mg ml -1 relative to AdEgr.TNF.11D plus gemcitabine 0, 0.001 and 0.01 mg ml -1 incubated cells. There was no significant relationship among Panc1 cells treated with AdEgr.TNF.11D plus gemcitabine at 40.1 mg ml -1 . The hTNF-a production can be increased in AdEgr.TNF.11D transduced cells after exposure to gemcitabine relative to AdEgr.TNF.11D-transduced cells without gemcitabine.
cancer cells. 13 We, therefore, examined the inducibility of AdEgr.TNF.11D by gemcitabine in three human pancreatic carcinoma cell lines (MiaPaca2, Panc1, and AsPC1). Human pancreatic cancer cells were exposed to AdEgr.TNF.11D (100 MOI) followed by gemcitabine treatment as described in the legend of Figure 1 . The TNF-a concentrations were determined using an ELISA specific to hTNF-a. The data from three different pancreatic cancer cell lines show that AdEgr.TNF.11D was inducible by gemcitabine, with generally increasing hTNF-a levels in samples as the gemcitabine dose was increased. The response was greatest in the MiaPaca2 and Panc1 cell lines, with maximum hTNF-a levels observed at the 1 mg ml -1 gemcitabine dose. Measured hTNF-a increased by 28-fold in MiaPaca2 and 9-fold in Panc1. A similar dose response was observed in the AsPC1 pancreatic carcinoma cell line, though the response was lower (data not shown).
Combined treatment with AdEgr.TNF.11D and gemcitabine enhances tumor growth delay in human pancreatic cancer models The effect of AdEgr.TNF.11D in combination with gemcitabine on tumor growth was examined using MiaPaca2 and AsPC1 tumors in mice. Xenografts were implanted and grown, tumor-bearing animals randomly assigned and treated as described in showed the greatest mean increases in tumor volume. Those in control vector group had similar increases in tumor volume until Day 9, after which mean tumor growth was delayed compared with the vehicle-injected mice. Notably, combined treatment with AdEgr.TNF.11D and gemcitabine produced the largest delays in tumor growth compared with the other treatment groups.
We found that the AdEgr.TNF.11D (TNFerade) alone or gemcitabine alone or combination treatment with AdEgr.TNF.11D and gemcitabine had a statistical significant (P ¼ 0.05) effect on the rate of tumor volume growth compared with vehicle control alone. The , the treatment was initiated. Each treatment group had n ¼ 8 animals. AdEgr.TNF.11D or Adf.11D (vector control without hTNF-a gene) was given intratumorally at 1 Â 10 10 pu per 30 ml three times a week for 2 weeks followed by one time a week for 2 weeks. Gemcitabine was administered intravenously through jugular vein at 120 mg kg -1 once a week for 4 weeks. For combination studies (AdEgr.TNF.11D þ gemcitabine), gemcitabine was administered 2 h after AdEgr.TNF.11D administration. Final formulation buffer was given as vehicle control. Tumor size was measured two or three times per week. Points represent tumor volume mean values ± s.d. for eight mice. Statistical analyses were determined from calculated log rate of tumor growth among vehicle, gemcitabine, AdEgr.TNF.11D and AdEgr.TNF.11D þ gemcitabine treatments and found to be as determined by the least square means (P ¼ 0.05, data not shown). The combined treatment with AdEgr.TNF.11D and gemcitabine had a greater anti-tumor activity than did either agent alone.
AdEgr.TNF.11D had greater significant effect (P ¼ 0.05) as a single therapy relative to gemcitabine alone. The effect of combination treatment was higher than that of gemcitabine alone and it was significant (P ¼ 0.05). Notably, the combination therapy had greater effect than did AdEgr.TNF.11D alone, and gemcitabine did not reduce the anti-tumor activity of AdEgr.TNF.11D. Thus, biologically, the combination at the doses tested was better than either agent alone, though statistically the combination was not found to be either additive or synergistic. For these studies, we used a moderate dose of gemcitabine, 120 mg kg -1 as compared with 240 mg kg -1 given intravenously in animal models. 16 This is equivalent to B362 mg m -2 per week, whereas the clinical dose for patients with pancreatic cancer is 1000 mg m -2 per week.
Combination treatment with AdEgr.TNF.11D and gemcitabine is well tolerated There were no detectable signs of treatment-related toxicity (e.g., skin discoloration, lethargy, skin ulceration and abnormal behavioral activity). The body weight was monitored during the course of the experiment as an indicator of toxicity. No major mean body weight loss was found in the AdEgr.TNF.11D or vehicle or control vector. However, an increased body weight change was observed for gemcitabine alone and for gemcitabine plus AdEgr.TNF.11D combination; this might be attributed to the impact of combining surgery with drugs. The administration of AdEgr.TNF.11D concomitant with gemcitabine resulted in mean loss in body weight by 8% over 25 days (Figure 3a and b) and was well tolerated. There were no treatment-related deaths in any of the groups.
Discussion
AdEgr.TNF.11D has been primarily investigated in animal models in combination with radiation. 6, [17] [18] [19] [20] In multiple cancer models tested to date including, esophageal, head and neck, melanoma, colon adenocarcinomas and gliomas, radiation is able to induce and regulate the expression of hTNF-a protein from the Egr-1 promoter in a dose-related manner. Moreover, by directing the radiation at the tumor and delivery of AdEgr.TNF.11D directly into the tumor, hTNF-a production is selectively limited to the tumor and the potent cytotoxic effects of hTNF-a on normal tissues are substantially reduced. The data in this paper show that gemcitabine, an agent commonly used in the treatment of pancreatic cancer, can also stimulate the production of hTNF-a protein from the Egr-1 promoter. In vitro studies using human pancreatic cancer cells showed that incubation with gemcitabine given at 1-10 mg ml -1 or approximately 3.3-30 mM, which is comparable with plasma concentrations (15-25 mM) in humans given gemcitabine, stimulated hTNF-a protein production to levels at or above that found with radiation exposure. [21] [22] [23] Our data confirm work by Weichselbaum and co-workers 13, 14 which showed that several chemotherapeutic agents are able to 'turn-on' the Egr-1 promoter. The activation of Egr-1 promoter in AdEgr.TNF.11D by gemcitabine is mediated, at least in part, by the induction of intracellular reactive oxygen radicals signals that target the CArG motif in the Egr-1 promoter resulting in hTNF-a production. 13 We tested the use of gemcitabine to up-regulate hTNF-a expression, and using a moderate dose of gemcitabine, 120 mg kg -1 as compared with 240 mg kg -1 given intravenously, 16 we found that the combination of gemcitabine and AdEgr.TNF.11D delayed tumor growth better than either agent alone. Although radiation is used in the treatment of patients with locally advanced pancreatic cancer, 24 once the disease has metastasized, the patients are no longer candidates for radiation therapy. Gemcitabine, on the other hand, is commonly used for treating metastatic pancreatic cancer and is administered systemically. We propose herein that the combination of hTNF-a and gemcitabine could provide another anti-cancer approach. Our data directly support the possibility of combining local control of the tumor by hTNF-a production from AdEgr.TNF.11D up-regulated by gemcitabine and using systemic gemcitabine to control metastatic disease. Moreover, gemcitabine inhibits cancer cell proliferation by premature termination of DNA synthesis and blocks cell growth, whereas hTNF-a causes hemorrhagic necrosis in tumors and apoptosis of endothelial cells within the tumor. 5, 25 Combining agents with differing mechanisms of action has been a guiding concept behind multimodality cancer therapy. Systemic chemotherapy has often combined with surgery or radiation therapy to improve both control of local and disseminated diseases. We, therefore, propose that combination of intratumoral AdEgr.TNF.11D and systemic gemcitabine for advanced pancreatic cancer patients may be a novel approach that could improve patient outcome.
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